Zydus Wellness Share Price to Come in Focus After Announcement to Liquidate Subsidiary Naturell (India) Pvt Ltd

Zydus Wellness has announced that it will liquidate its wholly owned subsidiary, Naturell (India) Private Limited (NIPL). This move was approved by the company’s board of directors during a meeting held on June 24, 2025.

What Has Been Decided?

Earlier, on June 17, NIPL’s board gave in-principle approval for voluntary liquidation. Now, Zydus Wellness has also approved the decision to liquidate and consolidate NIPL’s business with itself, on a going-concern basis.

This means that the business of NIPL will continue to operate but under Zydus Wellness instead of as a separate company.

Business Transfer Details

According to a regulatory filing, Zydus Wellness will take over all of NIPL’s business in exchange for the ₹3,900 crore investment it had made in the subsidiary. The filing also made it clear that this is not a sale or slump sale.

Zydus Wellness expects the voluntary liquidation to be completed on time, as per Indian laws, and after all required regulatory approvals.

How Important Was NIPL?

From the time of acquisition until March 31, 2025, NIPL had a turnover of ₹617 million, contributing 2.28% to Zydus Wellness' total revenue. Its net worth was ₹146 million, or just 0.26% of the parent company's net worth.

Zydus Wellness Share Price Performance

Zydus Wellness share price closed at ₹2,000, down 1.98% on Tuesday, but the news came after market hours. The stock has had a mixed performance recently—up 2.33% in June and 18.7% in Q1 FY26, but only 1.19% up year-to-date.

About Zydus Wellness

Zydus Wellness, a subsidiary of Zydus Lifesciences, owns popular health brands like Sugar Free, Everyuth, and Nutralite—the last of which is operated by NIPL.

Read more: ITR Filing 2025: How to Report Dividend Income?

Conclusion

By liquidating NIPL and merging its operations, Zydus Wellness is aiming to simplify its structure and improve operational efficiency. The move signals a strategic shift to streamline its business.

Disclaimer: This blog has been written exclusively for educational purposes. The securities mentioned are only examples and not recommendations. This does not constitute a personal recommendation/investment advice. It does not aim to influence any individual or entity to make investment decisions. Recipients should conduct their own research and assessments to form an independent opinion about investment decisions.

Investments in the securities market are subject to market risks. Read all the related documents carefully before investing.